Evaluate the Long-Term Safety and Efficacy of Evinacumab in Patients With Homozygous Familial Hypercholesterolemia
A phase 3 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 116 participants.
Also called NCT03409744
- Study
- In this atlas
Overview
- Design
- Interventional study; allocation not applicable; no masking; primary purpose treatment
- Phase
- Phase 3
- Enrolled
- 116 participants
- Sponsor
- Registry
-
NCT03409744 -
2017-003170-13
-
- Started
- (actual)
- Primary completion
- (actual)
- Completion
- (actual)
- Results first posted
- Countries
- United States, Australia, Austria, Canada, Czechia, France, Greece, Italy, Japan, Netherlands, South Africa, Ukraine
- Registry status
- Completed
Technical summary
Registry record NCT03409744. Allocation not applicable; no masking; primary purpose treatment. Start 2018-03-13 (actual); primary completion 2023-04-13 (actual). Results posted on 2024-04-30.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- Evaluate the Long-Term Safety and Efficacy of Evinacumab in Patients With Homozygous Familial Hypercholesterolemia
- Condition
- Homozygous Familial Hypercholesterolemia
- Intervention (Drug)
- evinacumab
- Lead sponsor
- Regeneron Pharmaceuticals
Record details
- Record id
cardio:ct-nct03409744- Content hash
179ed56aa7c6e1086627e5a9d247ccc66dd35ef58c4bc938e1a51dfb2125d1b7